News & Media

Press release Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2024

”Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened...

Read more
Press release
Medivir brings the Q1 webcast forward to 10 a.m. on April 30

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release
FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release
Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release
Medivir to present at Investing in Oncology Forum on April 10

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release Regulatory
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the...

Read more
Press release Regulatory
Medivir 2023 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2023 now is available at the...

Read more
Press release
Medivir to present at Swiss Nordic Bio in Zürich on March 7

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir to present at the Life Science Day in Gothenburg on March 6

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Change in Medivir's nomination committee before the 2024 AGM

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that that the nomination committee before the annual general meeting in...

Read more